brentuximab vedotin

Back to Drugs List

Associated Genetic Biomarkers

Associated Diseases

Overview

Generic Name(s):

brentuximab vedotin

Trade Name(s):

Adcetris

NCI Definition [1]:

An antibody-drug conjugate (ADC) directed against the tumor necrosis factor (TNF) receptor CD30 with potential antineoplastic activity. Brentuximab vedotin is generated by conjugating the chimeric anti-CD30 monoclonal antibody SGN-30 to the cytotoxic agent monomethyl auristatin E (MMAE) via a valine-citrulline peptide linker. Upon administration and internalization by CD30-positive tumor cells, brentuximab vedotin undergoes enzymatic cleavage, releasing MMAE into the cytosol; MMAE binds to tubulin and inhibits tubulin polymerization, which may result in G2/M phase arrest and tumor cell apoptosis. Transiently activated during lymphocyte activation, CD30 (tumor necrosis factor receptor superfamily, member 8;TNFRSF8) may be constitutively expressed in hematologic malignancies including Hodgkin lymphoma and some T-cell non-Hodgkin lymphomas. The linkage system in brentuximab vedotin is highly stable in plasma, resulting in cytotoxic specificity for CD30-positive cells.

Biomarker-Directed Therapies

Brentuximab vedotin can be used in the treatment of mature T-cell and NK-cell non-hodgkin lymphoma. TNFRSF8 Expression is the most frequent biomarker inclusion criterion for use of brentuximab vedotin [2].

Mature T-Cell And NK-Cell Non-Hodgkin Lymphoma +

Disease is predicted to be sensitive to brentuximab vedotin: -

Biomarker Criteria:

Sample must match one or more of the following:

TNFRSF8 Expression

Clinical Setting(s): First Line of Therapy (FDA)

Note: Approved brentuximab vedotin (ADCETRIS®, Seattle Genetics Inc.) in combination with chemotherapy for previously untreated systemic anaplastic large cell lymphoma (sALCL) or other CD30-expressing peripheral T-cell lymphomas (PTCL), including angioimmunoblastic T-cell lymphoma and PTCL not otherwise specified. This is the first FDA approval for previously untreated PTCL including sALCL.

Biomarker Criteria: Sample must match one or more of the following: TNFRSF8 Expression	Clinical Setting(s): First Line of Therapy (FDA)
	Note: Approved brentuximab vedotin (ADCETRIS®, Seattle Genetics Inc.) in combination with chemotherapy for previously untreated systemic anaplastic large cell lymphoma (sALCL) or other CD30-expressing peripheral T-cell lymphomas (PTCL), including angioimmunoblastic T-cell lymphoma and PTCL not otherwise specified. This is the first FDA approval for previously untreated PTCL including sALCL.

Clinical Trials

View Clinical Trials for brentuximab vedotin

Brentuximab vedotin has been investigated in 49 clinical trials, of which 46 are open and 3 are closed. Of the trials investigating brentuximab vedotin, 1 is early phase 1 (1 open), 3 are phase 1 (3 open), 7 are phase 1/phase 2 (6 open), 34 are phase 2 (32 open), and 4 are phase 3 (4 open).

TNFRSF8 Expression, TNFRSF8 Deficient Expression, and ALK Expression are the most frequent biomarker inclusion criteria for brentuximab vedotin clinical trials.

Classical hodgkin lymphoma, hodgkin lymphoma, and enteropathy-associated T-cell lymphoma are the most common diseases being investigated in brentuximab vedotin clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Brentuximab Vedotin

Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Brentuximab Vedotin

This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating brentuximab vedotin and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,931 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:

anti-cd30 antibody-drug conjugate sgn-35, 914088-09-8, brentuximab vedotin, anti-cd30 monoclonal antibody-mmae sgn-35, anti-cd30 adc sgn-35, antibody-drug conjugate sgn-35, Adcetris, sgn-35, brentuximab vedotin, anti-cd30 antibody-drug conjugate sgn-35, brentuximab vedotin (substance), brentuximab vedotin, anti-cd30 monoclonal antibody-monomethylauristatin e sgn-35, adc sgn-35, cac10-vcmmae, brentuximab vedotin (product)

Drug Target(s) [2]:

TNFRSF8

NCIT ID [1]:

C66944

SNOMED ID [1]:

F-D4641

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.

Drugs /